Hovione Unveils New Continuous Tableting Line at Lisbon R&D Centre
Hovione is proud to announce the opening of a state-of-the-art continuous tableting (CT) line at its R&D Center in Lisbon.
Oops! Your browser version is not supported by our website.
Please use these following browsers to view this page:
Hovione is proud to announce the opening of a state-of-the-art continuous tableting (CT) line at its R&D Center in Lisbon.
Hovione today announced an extension of collaboration on Zerion’s Dispersome® technology into the nutraceutical/dietary supplements field.
Presented by the Hénokiens Association and the Château du Clos Lucé
Safety First, Quality Always: We are continuously improving the safety of our operations with the patient’s safety in mind.
Outsourced Pharma, April 2023
C&EN, November 12, 2018
The agreement furthers Hovione´s ability to bring the benefits of continuous tableting, including reduced time to market and increased supply chain flexibility, to pharmaceutical customers globally